PAUL R. KIRCHGRABER
Executive Vice President, Chief Executive Officer, Drug Development
CEO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Labcorp Holdings Inc. (LH) | Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology | $630,000 | $3,016,933 |
| 2021 | Labcorp Holdings Inc. (LH) | Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology | $625,838 | $4,421,426 |
| 2020 | Labcorp Holdings Inc. (LH) | Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology | $606,000 | $2,973,651 |
Earnings-call appearances
No earnings-call appearances recorded yet.